Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Bello Roufai D, et al. Among authors: bertucci a. Oncogene. 2023 Apr;42(17):1417. doi: 10.1038/s41388-023-02615-8. Oncogene. 2023. PMID: 36922682 No abstract available.
PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.
Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M, Gonçalves A. Bertucci A, et al. Among authors: bertucci f. Front Oncol. 2020 Nov 25;10:575978. doi: 10.3389/fonc.2020.575978. eCollection 2020. Front Oncol. 2020. PMID: 33330051 Free PMC article.
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Bello Roufai D, et al. Among authors: bertucci a. Oncogene. 2023 Jun;42(23):1951-1956. doi: 10.1038/s41388-022-02585-3. Epub 2023 Jan 7. Oncogene. 2023. PMID: 36611120
GD3 ganglioside is a promising therapeutic target for glioma patients.
Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, Tabouret E. Hein V, et al. Among authors: bertucci a. Neurooncol Adv. 2024 Mar 19;6(1):vdae038. doi: 10.1093/noajnl/vdae038. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38590763 Free PMC article. Review.
94 results